Linked Life Data

17308051

Source:http://linkedlifedata.com/resource/pubmed/id/17308051

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-2-19
pubmed:abstractText
The angiogenic growth factor placenta growth factor (PlGF) is implicated in several pathologic processes, including the growth and spread of cancer. We found by immunohistochemistry that 36% to 60% and 65% of primary breast cancers express PlGF and its receptor Flt-1, respectively. These findings suggest that PlGF may be active in tumor growth and metastasis beyond its role in angiogenesis. It was found that exogenously added PlGF (2 nmol/L), in contrast to vascular endothelial growth factor (2 nmol/L), significantly stimulated in vitro motility and invasion of the human breast tumor lines MCF-7 and MDA-MB-231. A PlGF-2/Flt-1-inhibiting peptide, binding peptide 1 (BP1), that binds Flt-1 at or near the heparin-binding site was identified and synthesized. Both PlGF-stimulated motility and invasion were prevented by treatment with BP1 (P < 0.05), as well as by anti-PlGF antibody. Treatment of mice bearing s.c. MDA-MB-231 with BP1 (200 mug i.p., twice per week) decreased the number of spontaneous metastatic lung nodules by 94% (P < 0.02), whereas therapy of animals with orthotopic mammary fat pad tumors decreased pulmonary metastases by 82% (P < 0.02). These results indicate, for the first time, that PlGF stimulates the metastatic phenotype in these breast cancer cells, whereas therapy with a PlGF-2/Flt-1 heparin-blocking peptide reduces the growth and metastasis of human breast cancer xenografts.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1535-7163
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
524-31
pubmed:dateRevised
2009-11-25
pubmed:meshHeading
pubmed-meshheading:17308051-Animals, pubmed-meshheading:17308051-Antibodies, Monoclonal, pubmed-meshheading:17308051-Breast Neoplasms, pubmed-meshheading:17308051-Cell Movement, pubmed-meshheading:17308051-Flow Cytometry, pubmed-meshheading:17308051-Homeodomain Proteins, pubmed-meshheading:17308051-Humans, pubmed-meshheading:17308051-Immunoenzyme Techniques, pubmed-meshheading:17308051-Lung Neoplasms, pubmed-meshheading:17308051-Lymphatic Metastasis, pubmed-meshheading:17308051-Mice, pubmed-meshheading:17308051-Mice, Nude, pubmed-meshheading:17308051-Neoplasm Invasiveness, pubmed-meshheading:17308051-Neovascularization, Pathologic, pubmed-meshheading:17308051-Peptide Fragments, pubmed-meshheading:17308051-Pregnancy Proteins, pubmed-meshheading:17308051-Survival Rate, pubmed-meshheading:17308051-Transcription Factors, pubmed-meshheading:17308051-Transplantation, Heterologous, pubmed-meshheading:17308051-Vascular Endothelial Growth Factor Receptor-1
pubmed:year
2007
pubmed:articleTitle
Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts.
pubmed:affiliation
Garden State Cancer Center, Center for Molecular Medicine and Immunology, 520 Belleville Avenue, Belleville, NJ 07109, USA. ataylor@gscancer.org
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't